# Commission Decision of 18 December 2008 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2009 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council on substances that deplete the ozone layer (notified under document number C(2008) 8398) (Only the Dutch, English, French, German, Italian, Slovenian and Spanish texts are authentic) (2009/52/EC), Annex II: ESSENTIAL MEDICAL USES

Extent: E+W+S+N.I.

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:
Chiesi Farmaceutici SpA (IT)
Valeas SpA Pharmaceuticals (IT)
(VARI) SpA — LINDAL Group Italia (IT)

---
Source: https://www.legislation.gov.uk/eudn/2009/52/annex/II (the official version)
Page: https://openlegislation.uk/eu-decision-2009-52/annex-II
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.